Table 5.
PFS | OS | ||
Gene symbol | β | Gene symbol | β |
CYP2E | − 0.16 | CYP2E | − 0.08 |
PDE1A | 0.67 | PDE1A | 0.03 |
PDE4A | − 1.85 | PDE4A | − 0.18 |
PDE1B | 0.12 | ||
ADORA1 | 0.01 | ||
PFS ER− | PFS PR− | ||
Gene symbol | β | Gene symbol | β |
PDE4A | 1.24 | PDE4A | − 0.81 |
CACNA1S | 0.07 | CACNA1S | 0.47 |
RYR1 | − 0.56 | RYR1 | − 0.22 |
PDE1A | − 0.33 | PDE1C | 0.03 |
PDE4B | − 0.59 | SPECC1L | − 0.76 |
XDH | − 0.13 | ||
OS ER− | OS PR− | ||
Gene symbol | β | Gene symbol | β |
PDE4A | − 0.21 | PDE4A | − 1.03 |
CACNA1S | 0.20 | CACNA1S | 0.76 |
PDE1A | 1.06 | ADORA1 | 0.08 |
RYR1 | − 0.83 | SPECC1L | − 0.52 |
XDH | − 0.05 |
PFS and OS models (n = 247) without regard to sex steroid receptor status. PFS models with regard to either ER− (n = 101) or PR− (n = 96) carcinomas. OS models with regard to either ER− (n = 101) or PR− (n = 96) carcinomas